CA2527722C - Biodegradable poly(beta-amino esters) and uses thereof - Google Patents

Biodegradable poly(beta-amino esters) and uses thereof Download PDF

Info

Publication number
CA2527722C
CA2527722C CA2527722A CA2527722A CA2527722C CA 2527722 C CA2527722 C CA 2527722C CA 2527722 A CA2527722 A CA 2527722A CA 2527722 A CA2527722 A CA 2527722A CA 2527722 C CA2527722 C CA 2527722C
Authority
CA
Canada
Prior art keywords
polymer
pharmaceutical composition
integer
polymers
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2527722A
Other languages
English (en)
French (fr)
Other versions
CA2527722A1 (en
Inventor
Robert Langer
David M. Lynn
Daniel G. Anderson
Akin Akinc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of CA2527722A1 publication Critical patent/CA2527722A1/en
Application granted granted Critical
Publication of CA2527722C publication Critical patent/CA2527722C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/44—Polyester-amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/12—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/40—Polyesters derived from ester-forming derivatives of polycarboxylic acids or of polyhydroxy compounds, other than from esters thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
    • C08G63/685—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen
    • C08G63/6854—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/6856—Dicarboxylic acids and dihydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0273—Polyamines containing heterocyclic moieties in the main chain
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/0605—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms
    • C08G73/0611—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms with only one nitrogen atom in the ring, e.g. polypyrroles
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/0605—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms
    • C08G73/0616—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms with only two nitrogen atoms in the ring
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/02—Polyesters derived from dicarboxylic acids and dihydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L77/00—Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Compositions of derivatives of such polymers
    • C08L77/04—Polyamides derived from alpha-amino carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/02—Polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L99/00—Compositions of natural macromolecular compounds or of derivatives thereof not provided for in groups C08L89/00 - C08L97/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2527722A 2003-05-28 2004-05-26 Biodegradable poly(beta-amino esters) and uses thereof Expired - Lifetime CA2527722C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/446,444 2003-05-28
US10/446,444 US7427394B2 (en) 2000-10-10 2003-05-28 Biodegradable poly(β-amino esters) and uses thereof
PCT/US2004/016521 WO2004106411A2 (en) 2003-05-28 2004-05-26 Biodegradable poly(beta-amino esters) and uses thereof

Publications (2)

Publication Number Publication Date
CA2527722A1 CA2527722A1 (en) 2004-12-09
CA2527722C true CA2527722C (en) 2013-04-16

Family

ID=33489383

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2527722A Expired - Lifetime CA2527722C (en) 2003-05-28 2004-05-26 Biodegradable poly(beta-amino esters) and uses thereof

Country Status (9)

Country Link
US (1) US7427394B2 (https=)
EP (2) EP1903068B1 (https=)
JP (3) JP4740864B2 (https=)
AT (2) ATE475685T1 (https=)
CA (1) CA2527722C (https=)
DE (2) DE602004028418D1 (https=)
ES (2) ES2290737T3 (https=)
PT (1) PT1639029E (https=)
WO (1) WO2004106411A2 (https=)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137695B2 (en) * 2006-08-18 2012-03-20 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
US20080281041A1 (en) 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6998115B2 (en) * 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7223851B2 (en) * 2003-02-06 2007-05-29 General Dynamics Advanced Information Systems, Inc. Nucleic acid-binding polymers
US7309757B2 (en) 2003-06-20 2007-12-18 Agency For Science, Technology And Research Polymers for the delivery of bioactive agents and methods of their preparation
US7883720B2 (en) 2003-07-09 2011-02-08 Wisconsin Alumni Research Foundation Charge-dynamic polymers and delivery of anionic compounds
US7943179B2 (en) * 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
US20050123596A1 (en) * 2003-09-23 2005-06-09 Kohane Daniel S. pH-triggered microparticles
WO2005089123A2 (en) * 2004-03-04 2005-09-29 Massachusetts Institute Of Technology Therapeutic anti-cancer dna
WO2005110438A2 (en) * 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
KR20050102295A (ko) * 2004-04-21 2005-10-26 학교법인 포항공과대학교 리포좀 및 그 제조방법
US7358223B2 (en) * 2004-10-04 2008-04-15 Nitto Denko Corporation Biodegradable cationic polymers
ES2900801T3 (es) 2004-12-22 2022-03-18 Nitto Denko Corp Portador de fármacos y kit de portador de fármacos para inhibir la fibrosis
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
KR100732013B1 (ko) * 2005-03-18 2007-06-25 성균관대학교산학협력단 ｐＨ 민감성 블록 공중합체 및 이를 이용한 고분자 마이셀
WO2006118547A1 (en) * 2005-04-29 2006-11-09 Agency For Science, Technology And Research Hyperbranched polymers and their applications
US20060257355A1 (en) * 2005-05-10 2006-11-16 Abiomed, Inc. Impregnated polymer compositions and devices using them
US8101741B2 (en) 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
WO2007067733A2 (en) * 2005-12-09 2007-06-14 Massachusetts Institute Of Technology Compositions and methods to monitor rna delivery to cells
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
US7700541B2 (en) * 2006-04-06 2010-04-20 Nitto Denko Corporation Biodegradable cationic polymers
WO2007143659A2 (en) * 2006-06-05 2007-12-13 Massachusetts Institute Of Technology Crosslinked, degradable polymers and uses thereof
CN100428964C (zh) * 2006-06-29 2008-10-29 武汉理工大学 RGD多肽接枝聚(羟基乙酸-L-赖氨酸-L-乳酸)/β-磷酸三钙复合材料及其制备方法
CA2658768C (en) * 2006-07-21 2016-05-17 Massachusetts Institute Of Technology End-modified poly(beta-amino esters) and uses thereof
EP2099496A2 (en) * 2006-12-08 2009-09-16 Massachusetts Institute of Technology Delivery of nanoparticles and/or agents to cells
KR100825519B1 (ko) * 2007-01-05 2008-04-25 주식회사 바이오폴리메드 키토산 기재 고분자 접합체 및 그 제조방법
WO2008109806A2 (en) * 2007-03-08 2008-09-12 Massachusetts Institute Of Technology Electrostatic coating of particles for drug delivery
TWI407971B (zh) 2007-03-30 2013-09-11 日東電工股份有限公司 Cancer cells and tumor-related fibroblasts
WO2008157372A2 (en) 2007-06-14 2008-12-24 Massachusetts Institute Of Technology Self assembled films for protein and drug delivery applications
KR20100065190A (ko) 2007-09-14 2010-06-15 닛토덴코 가부시키가이샤 약물 담체
JP5484339B2 (ja) 2007-10-05 2014-05-07 ウェイン ステート ユニバーシティー 合成物の持続的な放出のためのデンドリマー
US20090105375A1 (en) * 2007-10-09 2009-04-23 Lynn David M Ultrathin Multilayered Films for Controlled Release of Anionic Reagents
JP5802389B2 (ja) * 2007-12-13 2015-10-28 ポリプラス−トランスフェクション 合成ポリマーを用いた遺伝子サイレンシングに活性な核酸を送達する手段
WO2009082817A1 (en) 2007-12-27 2009-07-09 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
EP2244697A1 (en) * 2008-01-29 2010-11-03 Shire Human Genetic Therapies, Inc. Therapeutic compositions
US20110218140A1 (en) * 2008-02-25 2011-09-08 Gonsalves Kenneth E Biodegradable therapeutic nanoparticles containing an antimicrobial agent
JP2011516094A (ja) 2008-04-15 2011-05-26 プロチバ バイオセラピューティクス インコーポレイティッド 干渉ｒｎａを用いたｃｓｎ５遺伝子発現のサイレンシング方法
US8324333B2 (en) 2008-06-05 2012-12-04 Wisconsin Alumni Research Foundation Anionic charge-dynamic polymers for release of cationic agents
CN102137658A (zh) 2008-06-30 2011-07-27 斯兰斯德有限公司 局部递送药物的方法、组合物和系统
WO2010021973A2 (en) 2008-08-17 2010-02-25 Massachusetts Institute Of Technology Controlled delivery of bioactive agents from decomposable films
ES2646630T3 (es) 2008-11-07 2017-12-14 Massachusetts Institute Of Technology Lipidoides aminoalcohólicos y usos de los mismos
HUE037082T2 (hu) 2008-11-10 2018-08-28 Arbutus Biopharma Corp Új lipidek és készítmények terápiás hatóanyagok szállítására
US8163861B2 (en) * 2009-01-15 2012-04-24 Living Proof, Inc. Beta-amino ester compounds and uses thereof
WO2010096286A1 (en) * 2009-02-18 2010-08-26 The Lubrizol Corporation Composition containing ester compounds and a method of lubricating an internal combustion engine
EP2408915A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010107952A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2408917A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
EP2408458A1 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521764A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた胸腺間質性リンパ球新生因子（ＴＳＬＰ）遺伝子発現のＲＮＡ干渉媒介性阻害
JP2012521760A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2010229847A1 (en) 2009-03-27 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of the intercellular adhesion molecule 1 (ICAM-1)gene expression using short interfering nucleic acid (siNA)
US20120004281A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010132879A2 (en) 2009-05-15 2010-11-18 The Johns Hopkins University Multicomponent degradable cationic polymers
US9717694B2 (en) 2009-05-15 2017-08-01 The Johns Hopkins University Peptide/particle delivery systems
HUE042177T2 (hu) 2009-12-01 2019-06-28 Translate Bio Inc Szteroidszármazék mRNS szállítására humán genetikai betegségekben
US20110280912A1 (en) * 2009-12-15 2011-11-17 Massachusetts Institute Of Technology Degradable polymer nanostructure materials
WO2011078457A2 (ko) 2009-12-22 2011-06-30 성균관대학교산학협력단 다이온성 복합체 마이셀을 형성하는 피에이치 민감성 블록공중합체 및 이를 이용한 약물 또는 단백질 전달체
KR101291642B1 (ko) * 2010-03-03 2013-08-01 성균관대학교산학협력단 폴리(아미도 아민) 올리고머 하이드로젤 조성물 및 이를 이용한 약물전달체
EP2545100A2 (en) 2010-03-09 2013-01-16 Council of Scientific & Industrial Research A biodegradable polymeric hydrogel composition
US8349308B2 (en) 2010-03-26 2013-01-08 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
EP2582387A2 (en) 2010-06-17 2013-04-24 The United States Of America As Represented By The Secretary, National Institutes Of Health Compositions and methods for treating inflammatory conditions
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
GB2482709A (en) * 2010-08-11 2012-02-15 Envirogene Ltd Tracer
WO2012027206A1 (en) 2010-08-24 2012-03-01 Merck Sharp & Dohme Corp. SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
EP2609135A4 (en) 2010-08-26 2015-05-20 Massachusetts Inst Technology POLY (BETA AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF
WO2012027467A1 (en) 2010-08-26 2012-03-01 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
US8642087B1 (en) 2010-11-05 2014-02-04 University Of Kentucky Research Foundation Compounds and methods for reducing oxidative stress
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
CN103917239B (zh) 2011-05-27 2016-10-05 20迈德医疗私人有限公司 纳米凝胶
PL3586861T3 (pl) 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
WO2013040552A2 (en) 2011-09-16 2013-03-21 Georgia Health Sciences University Methods of promoting immune tolerance
KR102451116B1 (ko) 2011-10-27 2022-10-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
AU2012340086A1 (en) 2011-11-17 2014-05-29 The Regents Of The University Of California Therapeutic RNA switches compositions and methods of use
BR112014014599A2 (pt) 2011-12-16 2017-06-13 Massachusetts Inst Technology polímeros de alfa-aminoamidina e uso dos mesmos
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
EP2817328A1 (en) 2012-02-21 2014-12-31 Institut National de la Santé et de la Recherche Médicale Tam receptors as virus entry cofactors
EP2817327A1 (en) 2012-02-21 2014-12-31 Institut National de la Sante et de la Recherche Medicale (INSERM) Tim receptors as virus entry cofactors
WO2013163234A1 (en) 2012-04-23 2013-10-31 Massachusetts Institute Of Technology Stable layer-by-layer coated particles
EP3536787A1 (en) 2012-06-08 2019-09-11 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof
CA2820236C (en) 2012-06-15 2022-07-19 The Royal Institution For The Advancement Of Learning/Mcgill University Non-viral nanoparticle-based delivery system
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
EP2882706A1 (en) 2012-08-13 2015-06-17 Massachusetts Institute of Technology Amine-containing lipidoids and uses thereof
US9687569B2 (en) * 2012-08-16 2017-06-27 University Of Washington Through Its Center For Commercialization Theranostic nanoparticle and methods for making and using the nanoparticle
KR101445265B1 (ko) * 2012-09-18 2014-09-30 포항공과대학교 산학협력단 히알루론산-핵산 접합체 및 이를 포함하는 핵산 전달용 조성물
WO2014134029A1 (en) 2013-02-26 2014-09-04 Massachusetts Institute Of Technology Nucleic acid particles, methods and use thereof
GB201304245D0 (en) * 2013-03-08 2013-04-24 Inst Quimic De Sarria Chemical compounds
PL3467108T3 (pl) 2013-03-14 2024-09-30 Translate Bio, Inc. Sposoby oczyszczania informacyjnego rna
KR20210122917A (ko) 2013-03-14 2021-10-12 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
WO2014150074A1 (en) 2013-03-15 2014-09-25 Massachusetts Institute Of Technology Compositions and methods for nucleic acid delivery
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
MX2016005238A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Formulaciones de lipidos para la administracion de acido ribonucleico mensajero.
EA034103B1 (ru) 2013-10-22 2019-12-27 Транслейт Био, Инк. СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
ES2707966T3 (es) 2013-10-22 2019-04-08 Translate Bio Inc Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
CN105705140A (zh) * 2013-11-05 2016-06-22 克隆技术实验室有限公司 干转染组合物及其制备和使用方法
PT3134506T (pt) 2014-04-25 2019-10-31 Translate Bio Inc Métodos de purificação de rna mensageiro
CA2946422C (en) 2014-04-30 2019-03-05 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
JP6557722B2 (ja) 2014-05-30 2019-08-07 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 核酸の送達のための生分解性脂質
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
EP3160959B1 (en) 2014-06-24 2023-08-30 Translate Bio, Inc. Stereochemically enriched compositions for delivery of nucleic acids
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
WO2016025643A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Brush-poly(glycoamidoamine)-lipids and uses thereof
CA2957721C (en) 2014-08-13 2021-04-13 The Johns Hopkins University Selective dendrimer delivery to brain tumors
EP2995318B1 (en) * 2014-09-09 2022-12-07 Istanbul Universitesi Rektorlugu Synthesis of nanoparticular gene carrier systems based on poly(beta-aminoesters)
BR112017006679A2 (pt) 2014-10-02 2017-12-26 Protiva Biotherapeutics Inc moléculas, composição, partícula, composição farmacêutica, métodos para silenciar a expressão de um gene, usos de uma partícula, métodos para melhorar um ou mais sintomas, métodos para tratar uma infecção, usos de uma composição, método para inibir a replicação do vírus da hepatite d
AU2015360794B2 (en) 2014-12-08 2021-07-08 The Board Of Regents Of The University Of Texas System Lipocationic polymers and uses thereof
US20180245074A1 (en) 2015-06-04 2018-08-30 Protiva Biotherapeutics, Inc. Treating hepatitis b virus infection using crispr
ES2949540T3 (es) 2015-06-19 2023-09-29 Massachusetts Inst Technology 2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula
CN108350455A (zh) 2015-07-29 2018-07-31 阿布特斯生物制药公司 用于使b型肝炎病毒基因表达沉默的组合物和方法
CN105131182B (zh) * 2015-09-06 2017-07-21 山东大学 普朗尼克‑聚(β‑氨基酯)聚合物及其合成和应用方法
GB201519375D0 (en) * 2015-11-03 2015-12-16 Univ Cardiff Photodynamic therapy complex
US10413616B2 (en) 2015-12-23 2019-09-17 Viking Scientific, Inc. Hydrogel prodrug for treatment
AU2017250295B2 (en) * 2016-04-14 2022-08-25 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US10188749B2 (en) * 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP3500294A4 (en) 2016-08-22 2020-07-29 Arbutus Biopharma Corporation ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B
JP7348063B2 (ja) 2017-01-05 2023-09-20 フレッド ハッチンソン キャンサー センター ワクチン効力を改善するためのシステム及び方法
EA201991747A1 (ru) 2017-02-27 2020-06-04 Транслейт Био, Инк. НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
MX2019013752A (es) 2017-05-16 2020-07-20 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
US12059476B2 (en) * 2017-10-10 2024-08-13 The Johns Hopkins University Biodegradable biomimetic particles
US11464860B2 (en) 2017-10-27 2022-10-11 Massachusetts Institute Of Technology Poly (beta-amino esters) and uses thereof
WO2019089567A1 (en) 2017-10-30 2019-05-09 Massachusetts Institute Of Technology Layer-by-layer nanoparticles for cytokine therapy in cancer treatment
EP3713603A1 (en) 2017-11-23 2020-09-30 Institut National de la Sante et de la Recherche Medicale (INSERM) New method for treating dengue virus infection
CN109954144B (zh) * 2017-12-14 2022-07-08 复旦大学 基于改性聚β-氨基酯材料的双级pH响应纳米粒及其制备方法
CN111629715A (zh) 2018-01-18 2020-09-04 弗莱德哈钦森癌症研究中心 通过调节细胞活化状态改变体内免疫细胞的炎症状态
CA3108544A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
CA3111076A1 (en) 2018-08-30 2020-03-05 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with myocardin and ascl1
CA3117781A1 (en) 2018-10-26 2020-04-30 Massachusetts Institute Of Technology Polymer-lipids and compositions
MX2021005969A (es) 2018-11-21 2021-09-14 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
EP3714913A1 (en) * 2019-03-29 2020-09-30 Picosun Oy Color coding
US20220202951A1 (en) * 2019-05-14 2022-06-30 Universidade De Coimbra Light-triggerable nanoparticle library of formulations for the controlled release of rnas
WO2020229744A1 (fr) 2019-05-16 2020-11-19 Gem Innov Procede de preparation de microcapsules biodegradables et microcapsules ainsi obtenues
WO2021002984A1 (en) 2019-05-30 2021-01-07 Massachusetts Institute Of Technology Peptide nucleic acid functionalized hydrogel microneedles for sampling and detection of interstitial fluid nucleic acids
WO2021007515A1 (en) 2019-07-11 2021-01-14 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with micrornas and other factors
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法
CN111568856B (zh) * 2020-06-24 2021-07-06 珠海舒桐医疗科技有限公司 一种阴道凝胶制剂及其制备方法
US11945946B2 (en) 2020-09-14 2024-04-02 Encapsys, Llc Polyurea and poly(beta-amino ester) capsules with enhanced degradability
CN115010991B (zh) * 2020-11-11 2025-04-25 绍兴瑞康生物科技有限公司 空间位阻可调型弱碱光稳定剂及其制备方法和应用
FR3116211A1 (fr) * 2020-11-17 2022-05-20 Gem'innov Procede de preparation de microcapsules biodegradables et utilisation des microcapsules ainsi obtenues
FR3116212B1 (fr) 2020-11-18 2022-12-30 Gem Innov Procede de preparation de microcapsules biodegradables et microcapsules ainsi obtenues
EP4000725A1 (en) 2020-11-19 2022-05-25 The Procter & Gamble Company Consumer product comprising poly acrylate and poly(beta-amino ester) delivery capsules with enhanced degradability
CN116472303A (zh) * 2020-11-19 2023-07-21 恩盖普有限公司 具有提高的降解性的聚丙烯酸酯和聚(β-酯)胶囊
CN112851934B (zh) * 2020-12-29 2022-05-10 浙江大学杭州国际科创中心 一种含N-氧化三级胺基团的聚(β-氨基酯)及其制备方法和应用
US12433847B2 (en) 2021-03-09 2025-10-07 Massachusetts Institute Of Technology Branched poly(-amino esters) for the delivery of nucleic acids
WO2023059806A1 (en) 2021-10-06 2023-04-13 Massachusetts Institute Of Technology Lipid nanoparticles for drug delivery to microglia in the brain
CN113929904B (zh) * 2021-10-14 2022-10-25 西安交通大学 一类功能性单链环状聚(β-氨基酯)及其制备方法和基因递送药物应用
CN118660710A (zh) 2021-10-20 2024-09-17 罗切斯特大学 用于年龄相关白质损失的竞争性治疗的分离神经胶质祖细胞
EP4183884A1 (en) * 2021-11-19 2023-05-24 Branca Bunus Limited A method of preparing a fraction of a starting polymer vector for gene therapy
EP4441120A1 (en) * 2021-11-30 2024-10-09 Massachusetts Institute of Technology Poly(?-amino ester) microparticles for micronutrient fortification
JP2026503871A (ja) * 2022-11-01 2026-02-02 ポステック・リサーチ・アンド・ビジネス・ディベロップメント・ファウンデーション イオン化部分を有するポリマーベースの核酸分子輸送体
CN116396476B (zh) * 2023-04-18 2026-02-24 西安交通大学 一类末端为两性离子功能化的高度支化聚（β-氨基酯）及其制备方法和应用
WO2025090427A1 (en) 2023-10-23 2025-05-01 University Of Rochester Glial-targeted relief of hyperexcitability in neurodegenerative diseases
CN118755084B (zh) * 2024-06-13 2025-09-16 浙江工业大学 用于mRNA递送的聚合物、利用该聚合物的脂质/聚合物杂化纳米粒及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1668502A1 (de) * 1967-11-07 1971-09-02 Nii Monomerow Dlja Sintetitsch Verfahren zur Herstellung von Akryl-und Methakrylestern
US4224365A (en) * 1978-05-15 1980-09-23 Glass Containers Corporation Method of coating glass containers and product
US4348511A (en) * 1980-05-07 1982-09-07 Ciba-Geigy Corporation Process for the preparation of crosslinked, unsaturated polymers and the polymers thus obtained
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5180424A (en) 1991-10-07 1993-01-19 Westvaco Corporation Michael addition aminopolyester resins as dilution extenders for zinc-containing metal resinate inks
US5364634A (en) * 1991-11-08 1994-11-15 Southwest Research Institute Controlled-release PH sensitive capsule and adhesive system and method
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
KR100266912B1 (ko) * 1992-02-28 2000-12-01 파라비 레이 조직접촉물질이며 방출조절운반체인 광중합성 생분해성 하이드로겔
US6020317A (en) * 1993-02-19 2000-02-01 Nippon Shinyaku Co. Ltd. Glycerol derivative, device and pharmaceutical composition
US5770637A (en) * 1996-05-01 1998-06-23 Johnson & Johnson Vision Products, Inc. Anti-bacterial, UV absorbable, tinted, metal-chelating polymers
US5904927A (en) * 1997-03-14 1999-05-18 Northeastern University Drug delivery using pH-sensitive semi-interpenetrating network hydrogels
US5962520A (en) * 1998-04-02 1999-10-05 The University Of Akron Hydrolytically unstable, biocompatible polymer
DE19822602A1 (de) * 1998-05-20 1999-11-25 Goldschmidt Ag Th Verfahren zur Herstellung von Polyaminosäureestern durch Veresterung von sauren Polyaminosäuren oder Umesterung von Polyaminosäureestern
US6998115B2 (en) * 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof

Also Published As

Publication number Publication date
PT1639029E (pt) 2007-09-26
ES2290737T3 (es) 2008-02-16
DE602004007518D1 (de) 2007-08-23
US7427394B2 (en) 2008-09-23
ATE366769T1 (de) 2007-08-15
JP2007504353A (ja) 2007-03-01
EP1639029A2 (en) 2006-03-29
WO2004106411A3 (en) 2005-01-20
EP1639029B1 (en) 2007-07-11
JP5558154B2 (ja) 2014-07-23
EP1903068A1 (en) 2008-03-26
ATE475685T1 (de) 2010-08-15
DE602004028418D1 (de) 2010-09-09
US20040071654A1 (en) 2004-04-15
EP1903068B1 (en) 2010-07-28
DE602004007518T2 (de) 2008-03-20
WO2004106411A2 (en) 2004-12-09
JP4740864B2 (ja) 2011-08-03
JP2010180412A (ja) 2010-08-19
CA2527722A1 (en) 2004-12-09
JP2014129536A (ja) 2014-07-10
ES2350055T3 (es) 2011-01-17

Similar Documents

Publication Publication Date Title
CA2527722C (en) Biodegradable poly(beta-amino esters) and uses thereof
USRE43612E1 (en) Biodegradable poly(β-amino esters) and uses thereof
US9700627B2 (en) Biodegradable poly (beta-amino esters) and uses thereof
US7943179B2 (en) pH triggerable polymeric particles
US7883720B2 (en) Charge-dynamic polymers and delivery of anionic compounds
WO2005055979A2 (en) Ph triggerable polymeric particles or films containing a poly (beta-amino ester)
CA2658768A1 (en) End-modified poly(beta-amino esters) and uses thereof

Legal Events

Date Code Title Description
EEER Examination request